## FDA Issues Warning Letters to 30 Telehealth Firms Over Misleading Claims on Compounded GLP-1 Drugs
The U.S. Food and Drug Administration (FDA) has taken regulatory action against 30 telehealth companies, issuing formal warning letters concerning their marketing and promotion of compounded versions of popular glucagon-like peptide-1 (GLP-1) agonist drugs, such as Ozempic (semaglutide) and Zepbound (tirzepatide). The agency's primary concern centers on misleading claims made by these companies regarding the safety, efficacy, and regulatory status of these compounded products. Compounded drugs are mixed, combined, or altered by pharmacists to create tailored medications for individual patients, often when an FDA-approved drug is unavailable. The FDA has not approved compounded versions of semaglutide or tirzepatide for weight loss. The warning letters allege that the targeted companies have made false or misleading statements, potentially downplaying risks and creating confusion for consumers seeking weight-loss treatments. This action highlights the FDA's ongoing scrutiny of the rapidly expanding market for weight-management medications and its efforts to police the digital health sector, where direct-to-consumer advertising and online prescribing have surged. Patients are advised to obtain prescription medications, including GLP-1 agonists, through licensed healthcare providers and to be cautious of products marketed online that make broad claims about weight loss.
---
- **Source**: 
- **Sector**: The Lab
- **Tags**: fda, telehealth, glp-1, weight loss, pharmacists
- **Credibility**: unverified
- **Published**: 2026-03-05 19:42:56
- **ID**: 2087
- **URL**: https://whisperx.ai/en/intel/2087